Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Alterity Therapeutics ( (ATHE) ).
On October 14, 2025, Alterity Therapeutics Limited reported a change in substantial holding as per a notice filed by Regal Funds Management Pty Limited. The change, which occurred on October 10, 2025, increased Regal’s voting power in Alterity from 13.76% to 14.93%. This adjustment in holdings reflects a strategic move by Regal Funds Management, potentially impacting Alterity’s shareholder dynamics and influencing future corporate decisions.
The most recent analyst rating on (ATHE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the ATHE Stock Forecast page.
Spark’s Take on ATHE Stock
According to Spark, TipRanks’ AI Analyst, ATHE is a Neutral.
Alterity Therapeutics faces significant challenges with profitability and cash flow, which are critical for its long-term success. The technical indicators suggest a bearish trend, and the valuation metrics highlight the company’s unprofitability. These factors collectively contribute to a low overall stock score.
To see Spark’s full report on ATHE stock, click here.
More about Alterity Therapeutics
Alterity Therapeutics Limited is a development stage enterprise in the biotechnology industry, primarily focused on developing therapeutic products for neurodegenerative diseases. The company is headquartered in Melbourne, Australia.
Average Trading Volume: 139,083
Technical Sentiment Signal: Buy
Current Market Cap: $77.79M
For a thorough assessment of ATHE stock, go to TipRanks’ Stock Analysis page.